BSE:532660

Stock Analysis Report

Executive Summary

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals in India, Mexico, Spain, Hungary, and internationally.


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has Vivimed Labs's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 532660's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.8%

532660

8.9%

IN Pharmaceuticals

9.3%

IN Market


1 Year Return

-69.6%

532660

-17.1%

IN Pharmaceuticals

-29.6%

IN Market

Return vs Industry: 532660 underperformed the Indian Pharmaceuticals industry which returned -22.1% over the past year.

Return vs Market: 532660 underperformed the Indian Market which returned -30.6% over the past year.


Shareholder returns

532660IndustryMarket
7 Day2.8%8.9%9.3%
30 Day-30.0%-8.8%-23.3%
90 Day-42.6%-10.2%-28.0%
1 Year-69.6%-69.6%-15.8%-17.1%-28.2%-29.6%
3 Year-93.0%-93.1%-25.6%-27.5%-15.8%-20.5%
5 Year-89.8%-89.9%-37.2%-39.4%-4.7%-9.6%

Price Volatility Vs. Market

How volatile is Vivimed Labs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Vivimed Labs undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 532660 (₹7.26) is trading below our estimate of fair value (₹267.86)

Significantly Below Fair Value: 532660 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 532660 is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 532660 is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 532660's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 532660 is good value based on its PB Ratio (0.1x) compared to the IN Pharmaceuticals industry average (1x).


Next Steps

Future Growth

How is Vivimed Labs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vivimed Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vivimed Labs performed over the past 5 years?

-12.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 532660 is currently unprofitable.

Growing Profit Margin: 532660 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 532660 is unprofitable, and losses have increased over the past 5 years at a rate of -12.9% per year.

Accelerating Growth: Unable to compare 532660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 532660 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).


Return on Equity

High ROE: 532660 has a negative Return on Equity (-5.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is Vivimed Labs's financial position?


Financial Position Analysis

Short Term Liabilities: 532660's short term assets (₹10.6B) exceed its short term liabilities (₹7.4B).

Long Term Liabilities: 532660's short term assets (₹10.6B) exceed its long term liabilities (₹4.8B).


Debt to Equity History and Analysis

Debt Level: 532660's debt to equity ratio (89.9%) is considered high.

Reducing Debt: 532660's debt to equity ratio has reduced from 150.7% to 89.9% over the past 5 years.


Balance Sheet

Inventory Level: 532660 has a high level of physical assets or inventory.

Debt Coverage by Assets: 532660's debt is covered by short term assets (assets are 1.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 532660 has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: Insufficient data to determine if 532660 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Vivimed Labs's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 532660's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 532660's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 532660's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 532660's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 532660 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 532660's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Santosh Varalwar (57yo)

no data

Tenure

₹6,000,004

Compensation

Mr. Santosh Varalwar has been the Managing Director of Vivimed Labs Limited since January 27, 2004 and has been its Executive Director since November 09, 1989. Mr. Varalwar served as Chief Executive Office ...


CEO Compensation Analysis

Compensation vs Market: Santosh's total compensation ($USD79.63K) is above average for companies of similar size in the Indian market ($USD48.16K).

Compensation vs Earnings: Santosh's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Santosh Varalwar
MD & Executive Directorno data₹6.00m6.75% 40.6m
Srirambatla Raghunandan
CFO & Whole-Time Director12.25yrs₹5.00m0.38% 2.3m
Yugandhar Kopparthi
Compliance Officer & Company Secretaryno data₹2.29mno data
Manohar Varalwar
Whole Time Director25.42yrs₹6.00m1.56% 9.4m
Sandeep Varalwar
Whole Time Director12.25yrs₹6.00m2.26% 13.6m
Snehashree Joshi
Assistant Compant Secretaryno datano datano data
Amarjit Bhatia
Advisor of Vivimed Group4yrs₹4.38mno data

1.4yrs

Average Tenure

57yo

Average Age

Experienced Management: 532660's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Santosh Varalwar
MD & Executive Directorno data₹6.00m6.75% 40.6m
Srirambatla Raghunandan
CFO & Whole-Time Director12.25yrs₹5.00m0.38% 2.3m
Manohar Varalwar
Whole Time Director25.42yrs₹6.00m1.56% 9.4m
Sandeep Varalwar
Whole Time Director12.25yrs₹6.00m2.26% 13.6m
Subhash Varalwar
Non-Executive Promoter Director30.42yrs₹225.00k1.95% 11.7m
Mamidpalli Rao
Independent Non-Executive Chairmanno data₹425.00kno data
Umanath Varahabhotla
Independent Non-Executive Director5.08yrs₹375.00kno data

18.8yrs

Average Tenure

59yo

Average Age

Experienced Board: 532660's board of directors are seasoned and experienced ( 18.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 532660 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vivimed Labs Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vivimed Labs Limited
  • Ticker: 532660
  • Exchange: BSE
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹601.955m
  • Shares outstanding: 82.91m
  • Website: https://www.vivimedlabs.com

Number of Employees


Location

  • Vivimed Labs Limited
  • North End
  • Road No.2
  • Hyderabad
  • Andhra Pradesh
  • 500034
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532660BSE (Mumbai Stock Exchange)INR2ININRNo data
532660BSE (Mumbai Stock Exchange)YesEquity SharesININRAug 2005
VIVIMEDLABNSEI (National Stock Exchange of India)YesEquity SharesININRAug 2005

Biography

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals in India, Mexico, Spain, Hungary, and internationally. It operates through two segments, Specialty Chemicals Business and Pharma Business. The company is involved in the provision of APIs and intermediates for various generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. The company’s products are used in home care, personal care, and industrial product categories. Vivimed Labs Limited was incorporated in 1988 and is headquartered in Hyderabad, India. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 12:51
End of Day Share Price2020/04/01 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.